SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-24-071928
Filing Date
2024-08-22
Accepted
2024-08-22 17:23:46
Documents
2
Group Members
GREENSTAR, L.P.ILAN LEVINMORINGA PARTNERS LTD.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea0212167-13dmoringa_silex.htm SC 13D 151671
2 JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) ea021216701ex99-1_silexion.htm EX-99.1 6073
  Complete submission text file 0001213900-24-071928.txt   159580
Mailing Address C/O MORINGA ACQUISITION CORP 250 PARK AVENUE, 7TH FLOOR NEW YORK NY 11040
Business Address C/O MORINGA ACQUISITION CORP 250 PARK AVENUE, 7TH FLOOR NEW YORK NY 11040 (212) 572-6395
Moringa Sponsor, LP (Filed by) CIK: 0001849192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871
Business Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871 972-8-6286005
Silexion Therapeutics Corp (Subject) CIK: 0002022416 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-94600 | Film No.: 241232862
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)